Healthcare giant Healius (ASX:HLS) has reported a resilient performance for the first half of the 2026 financial year, underscored by a return to profitability in its underlying earnings.
The group saw total revenue climb 3.8% to $688.1 million, driven largely by its core pathology division and a standout performance from its Agilex business.
The company’s underlying EBIT swung to a $7.9 million profit, a significant recovery from the $2.7 million loss recorded in the prior corresponding period.
The turnaround was supported by a 13.1% surge in underlying EBITDA, which reached $122.2 million.
While the reported NPAT showed a $30.4 million loss due to non-underlying items and discontinued operations, the operational metrics suggest a stabilising core.
The Pathology division remains the engine room of the group, with revenues rising 3.5% to $666.3 million.
Although volume growth was modest at 1.2%, the company improved its average fee by 3.5% by shifting its focus toward higher-value areas such as Genomics, B2B clinical trials, and Veterinary Pathology.
The strategic pivot helped offset a challenging broader market environment.
Total GP attendances fell by 1.5% as telehealth continues to gain traction, and recent Medicare changes to B12 and urine testing criteria impacted traditional testing volumes.